Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Olfactory neuroblastoma Indication Strategy Report 2026: DLL3, Trials and Deals
23 July 2026
2026 Olfactory neuroblastoma strategy: epidemiology, DLL3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pituitary neuroendocrine tumor Indication Strategy Report 2026: SSTR2, Trials and Deals
23 July 2026
2026 Pituitary neuroendocrine tumor strategy: epidemiology, SSTR2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Malignant rhabdoid tumor Indication Strategy Report 2026: SMARCB1, Trials and Deals
23 July 2026
2026 Malignant rhabdoid tumor strategy: epidemiology, SMARCB1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Craniopharyngioma Indication Strategy Report 2026: BRAF, Trials and Deals
23 July 2026
2026 Craniopharyngioma strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Atypical teratoid rhabdoid tumor Indication Strategy Report 2026: SMARCB1, Trials and Deals
23 July 2026
2026 Atypical teratoid rhabdoid tumor strategy: epidemiology, SMARCB1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pancreatoblastoma Indication Strategy Report 2026: CTNNB1, Trials and Deals
23 July 2026
2026 Pancreatoblastoma strategy: epidemiology, CTNNB1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Pleuropulmonary blastoma Indication Strategy Report 2026: DICER1, Trials and Deals
23 July 2026
2026 Pleuropulmonary blastoma strategy: epidemiology, DICER1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Fibrolamellar hepatocellular carcinoma Indication Strategy Report 2026: DNAJB1-PRKACA, Trials and Deals
23 July 2026
2026 Fibrolamellar hepatocellular carcinoma strategy: epidemiology, DNAJB1-PRKACA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Perihilar cholangiocarcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
23 July 2026
2026 Perihilar cholangiocarcinoma strategy: epidemiology, KRAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Distal cholangiocarcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
23 July 2026
2026 Distal cholangiocarcinoma strategy: epidemiology, KRAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Intrahepatic cholangiocarcinoma Indication Strategy Report 2026: FGFR2, Trials and Deals
23 July 2026
2026 Intrahepatic cholangiocarcinoma strategy: epidemiology, FGFR2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Esophageal squamous cell carcinoma Indication Strategy Report 2026: PD-1, Trials and Deals
23 July 2026
2026 Esophageal squamous cell carcinoma strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.